The HCV Synthesis Project

Scope, methodology, and preliminary results

Rebecca K. Stern, Holly Hagan, Corina Lelutiu-Weinberger, Don Des Jarlais, Roberta Scheinmann, Shiela Strauss, Enrique R. Pouget, Peter Flom

Research output: Contribution to journalArticle

Abstract

Background. The hepatitis C virus (HCV) is hyper-endemic in injecting drug users. There is also excess HCV among non-injection drug users who smoke, snort, or sniff heroin, cocaine, crack, or methamphetamine. Methods. To summarize the research literature on HCV in drug users and identify gaps in knowledge, we conducted a synthesis of the relevant research carried out between 1989 and 2006. Using rigorous search methods, we identified and extracted data from published and unpublished reports of HCV among drug users. We designed a quality assurance system to ensure accuracy and consistency in all phases of the project. We also created a set of items to assess study design quality in each of the reports we included. Results. We identified 629 reports containing HCV prevalence rates, incidence rates and/or genotype distribution among injecting or non-injecting drug user populations published between January 1989 and December 2006. The majority of reports were from Western Europe (41%), North America (26%), Asia (11%) and Australia/New Zealand (10%). We also identified reports from Eastern Europe, South America, the Middle East, and the Caribbean. The number of publications reporting HCV rates in drug users increased dramatically between 1989 and 2006 to 27-52 reports per year after 1998. Conclusion. The data collection and quality assurance phases of the HCV Synthesis Project have been completed. Recommendations for future research on HCV in drug users have come out of our data collection phase. Future research reports can enhance their contributions to our understanding of HCV etiology by clearly defining their drug user participants with respect to type of drug and route of administration. Further, the use of standard reporting methods for risk factors would enable data to be combined across a larger set of studies; this is especially important for HCV seroconversion studies which suffer from small sample sizes and low power to examine risk factors.

Original languageEnglish (US)
Article number62
JournalBMC Medical Research Methodology
Volume8
DOIs
StatePublished - 2008

Fingerprint

Hepacivirus
Drug Users
Drug Administration Routes
Crack Cocaine
Eastern Europe
Middle East
Methamphetamine
South America
Heroin
North America
New Zealand
Research
Smoke
Sample Size
Publications
Genotype
Incidence

ASJC Scopus subject areas

  • Epidemiology
  • Health Informatics

Cite this

The HCV Synthesis Project : Scope, methodology, and preliminary results. / Stern, Rebecca K.; Hagan, Holly; Lelutiu-Weinberger, Corina; Des Jarlais, Don; Scheinmann, Roberta; Strauss, Shiela; Pouget, Enrique R.; Flom, Peter.

In: BMC Medical Research Methodology, Vol. 8, 62, 2008.

Research output: Contribution to journalArticle

Stern, Rebecca K. ; Hagan, Holly ; Lelutiu-Weinberger, Corina ; Des Jarlais, Don ; Scheinmann, Roberta ; Strauss, Shiela ; Pouget, Enrique R. ; Flom, Peter. / The HCV Synthesis Project : Scope, methodology, and preliminary results. In: BMC Medical Research Methodology. 2008 ; Vol. 8.
@article{01b7b0c3ed6741c2b320710954909176,
title = "The HCV Synthesis Project: Scope, methodology, and preliminary results",
abstract = "Background. The hepatitis C virus (HCV) is hyper-endemic in injecting drug users. There is also excess HCV among non-injection drug users who smoke, snort, or sniff heroin, cocaine, crack, or methamphetamine. Methods. To summarize the research literature on HCV in drug users and identify gaps in knowledge, we conducted a synthesis of the relevant research carried out between 1989 and 2006. Using rigorous search methods, we identified and extracted data from published and unpublished reports of HCV among drug users. We designed a quality assurance system to ensure accuracy and consistency in all phases of the project. We also created a set of items to assess study design quality in each of the reports we included. Results. We identified 629 reports containing HCV prevalence rates, incidence rates and/or genotype distribution among injecting or non-injecting drug user populations published between January 1989 and December 2006. The majority of reports were from Western Europe (41{\%}), North America (26{\%}), Asia (11{\%}) and Australia/New Zealand (10{\%}). We also identified reports from Eastern Europe, South America, the Middle East, and the Caribbean. The number of publications reporting HCV rates in drug users increased dramatically between 1989 and 2006 to 27-52 reports per year after 1998. Conclusion. The data collection and quality assurance phases of the HCV Synthesis Project have been completed. Recommendations for future research on HCV in drug users have come out of our data collection phase. Future research reports can enhance their contributions to our understanding of HCV etiology by clearly defining their drug user participants with respect to type of drug and route of administration. Further, the use of standard reporting methods for risk factors would enable data to be combined across a larger set of studies; this is especially important for HCV seroconversion studies which suffer from small sample sizes and low power to examine risk factors.",
author = "Stern, {Rebecca K.} and Holly Hagan and Corina Lelutiu-Weinberger and {Des Jarlais}, Don and Roberta Scheinmann and Shiela Strauss and Pouget, {Enrique R.} and Peter Flom",
year = "2008",
doi = "10.1186/1471-2288-8-62",
language = "English (US)",
volume = "8",
journal = "BMC Medical Research Methodology",
issn = "1471-2288",
publisher = "BioMed Central",

}

TY - JOUR

T1 - The HCV Synthesis Project

T2 - Scope, methodology, and preliminary results

AU - Stern, Rebecca K.

AU - Hagan, Holly

AU - Lelutiu-Weinberger, Corina

AU - Des Jarlais, Don

AU - Scheinmann, Roberta

AU - Strauss, Shiela

AU - Pouget, Enrique R.

AU - Flom, Peter

PY - 2008

Y1 - 2008

N2 - Background. The hepatitis C virus (HCV) is hyper-endemic in injecting drug users. There is also excess HCV among non-injection drug users who smoke, snort, or sniff heroin, cocaine, crack, or methamphetamine. Methods. To summarize the research literature on HCV in drug users and identify gaps in knowledge, we conducted a synthesis of the relevant research carried out between 1989 and 2006. Using rigorous search methods, we identified and extracted data from published and unpublished reports of HCV among drug users. We designed a quality assurance system to ensure accuracy and consistency in all phases of the project. We also created a set of items to assess study design quality in each of the reports we included. Results. We identified 629 reports containing HCV prevalence rates, incidence rates and/or genotype distribution among injecting or non-injecting drug user populations published between January 1989 and December 2006. The majority of reports were from Western Europe (41%), North America (26%), Asia (11%) and Australia/New Zealand (10%). We also identified reports from Eastern Europe, South America, the Middle East, and the Caribbean. The number of publications reporting HCV rates in drug users increased dramatically between 1989 and 2006 to 27-52 reports per year after 1998. Conclusion. The data collection and quality assurance phases of the HCV Synthesis Project have been completed. Recommendations for future research on HCV in drug users have come out of our data collection phase. Future research reports can enhance their contributions to our understanding of HCV etiology by clearly defining their drug user participants with respect to type of drug and route of administration. Further, the use of standard reporting methods for risk factors would enable data to be combined across a larger set of studies; this is especially important for HCV seroconversion studies which suffer from small sample sizes and low power to examine risk factors.

AB - Background. The hepatitis C virus (HCV) is hyper-endemic in injecting drug users. There is also excess HCV among non-injection drug users who smoke, snort, or sniff heroin, cocaine, crack, or methamphetamine. Methods. To summarize the research literature on HCV in drug users and identify gaps in knowledge, we conducted a synthesis of the relevant research carried out between 1989 and 2006. Using rigorous search methods, we identified and extracted data from published and unpublished reports of HCV among drug users. We designed a quality assurance system to ensure accuracy and consistency in all phases of the project. We also created a set of items to assess study design quality in each of the reports we included. Results. We identified 629 reports containing HCV prevalence rates, incidence rates and/or genotype distribution among injecting or non-injecting drug user populations published between January 1989 and December 2006. The majority of reports were from Western Europe (41%), North America (26%), Asia (11%) and Australia/New Zealand (10%). We also identified reports from Eastern Europe, South America, the Middle East, and the Caribbean. The number of publications reporting HCV rates in drug users increased dramatically between 1989 and 2006 to 27-52 reports per year after 1998. Conclusion. The data collection and quality assurance phases of the HCV Synthesis Project have been completed. Recommendations for future research on HCV in drug users have come out of our data collection phase. Future research reports can enhance their contributions to our understanding of HCV etiology by clearly defining their drug user participants with respect to type of drug and route of administration. Further, the use of standard reporting methods for risk factors would enable data to be combined across a larger set of studies; this is especially important for HCV seroconversion studies which suffer from small sample sizes and low power to examine risk factors.

UR - http://www.scopus.com/inward/record.url?scp=52249085658&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=52249085658&partnerID=8YFLogxK

U2 - 10.1186/1471-2288-8-62

DO - 10.1186/1471-2288-8-62

M3 - Article

VL - 8

JO - BMC Medical Research Methodology

JF - BMC Medical Research Methodology

SN - 1471-2288

M1 - 62

ER -